OS Therapies, Inc. (OSTX) Forward Price-to-Revenue Multiple
OS Therapies Incorporated (OSTX) enjoys deep trust from pediatric oncologists and specialized funds as a bold scientific visionary. The business's forward P/S helps track the dynamics of this sector, and the metric has currently reached the level of . Growth is driven by FDA Fast Track designations and M&A prospects, while the strategy relies on a listeria platform to combat solid tumors.
OSTX (OS Therapies, Inc.): analytical breakdowns and indicator data
- market price and analyst price targets:
- market capitalization details:
- business book valuation details:
- debt and solvency information:
Total Debt to Capital OS Therapies Incorporated|OSTX - Long-Term Liabilities to Capital|Short-Term Debt to Equity OS Therapies Incorporated|OSTX - Aggregate Debt Obligations|Debts to Book Capitalization OS Therapies, Inc.|OSTX - Company Long-Term Debts|Company Short-Term Debt OS Therapies|Quick Ratio ostherapies.com
- net income and valuation multiples indicators:
OSTX - Net Financial Result|Projected Future Earnings OS Therapies Incorporated|OSTX - Market Cap to Earnings|Future Price to Earnings OS Therapies Inc|OSTX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio OS Therapies, Inc.|OSTX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) OS Therapies|OSTX - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months ostherapies.com|OSTX - Earnings per share growth this year|Earnings growth forecast for next year OS Therapies Incorporated
- issuer revenue and sales details:
Summary company analysis:OS Therapies OSTX
The forward P/S ratio correlates the current market value of OS Therapies Incorporated (OSTX) with revenue forecasts, allowing for an assessment of the premium paid for future cash flows. The trend of the expected revenue multiple on GURU.Markets reflects market confidence in the success of the company's diversified oncology drug portfolio, where the distribution of risks across different trial stages directly impacts the asset's investment attractiveness.
Competitors of OS Therapies Incorporated
Price-to-Projected Revenue Ratio BeiGene ONC|Market Cap to Expected Sales Ratio Halozyme Therapeutics, Inc. (HALO)|RVMD: Forward Price-to-Revenue Multiple|Forward Price to Sales AAPG (Ascentage Pharma Corp)|CGON (CG Oncology, Inc.) - Forward Price-to-Revenue Multiple|URGN: Price to Expected Revenue Ratio|BCAX (Bicara Therapeutics) - Forward P/S Multiple|PSNL: Forward Price to Sales|Forward P/S Multiple ERAS|DCTH - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Y-mAbs Therapeutics YMAB|Forward Price to Sales AURA|Candel - Forward P/S Multiple|ARAY - Forward P/S Multiple|sellaslifesciences.com (SLS) - Price-to-Projected Revenue Ratio|Future Price to Revenue ACTU (Actuate Therapeutics Inc)|CTOR (Citius Oncology, Inc.) - Forward P/S Multiple|TuHURA (HURA) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TARA|FATE - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Aadi Bioscience WHWK|Market Cap to Expected Sales Ratio TScan Therapeutics Inc (TCRX)|CSBR: Forward Price-to-Revenue Multiple|Forward Price to Sales XBIT (XBiotech Inc.)|CVM: Forward P/S Multiple|RADX - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Artiva Biotherapeutics Inc.|Market Cap to Projected Revenue ANL (Adlai Nortye Limited)|Forward P/S Multiple VERU|Forward Price-to-Revenue Multiple tempesttx.com TPST|Price-to-Projected Revenue Ratio Xilio Therapeutics XLO|Renovaro Biosciences (RENB) - Market Cap to Future Revenue Ratio|MURA - Price-to-Projected Revenue Ratio|Forward Price to Sales KAPA (Kairos Pharma Ltd)|onkuretherapeutics.com (OKUR) - Price-to-Projected Revenue Ratio|Future Price to Revenue GDTC (CytoMed Therapeutics Limited)|Price-to-Projected Revenue Ratio Curis Inc.|Market Cap to Future Revenue Ratio Apollomics Corp APLM|Price-to-Projected Revenue Ratio Tharimmune Corp (THAR)|ADVB (advanbiomed.com) - Forward Price to Sales|Forward P/S Multiple GNPX (Genprex, Inc.)|Forward P/S Multiple Calidi Biotherapeutics Inc. CLDI|SBFM: Forward Price-to-Revenue Multiple|Xenetic Biosciences - Price to Expected Revenue Ratio|SLRX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Kitov Pharma (PPBT)|AONC (American Oncology Network Inc) - Forward P/S Multiple|Market Cap to Projected Revenue BGNE (beigene.com)|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|ELEV - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio iCAD ICAD|Market Cap to Expected Sales Ratio Ikena Oncology Inc. (IKNA)|NTBL: Forward Price-to-Revenue Multiple|Viracta Therapeutics - Price to Expected Revenue Ratio|MOR (MorphoSys) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue NAYA|AAPGV (Ascentage Pharma Group Ltd) - Forward P/S Multiple
